Prescription ·Strong evidence ·Reviewed May 2026
Liraglutide is a once-daily injectable GLP-1 receptor agonist approved for type 2 diabetes (Victoza, up to 1.8 mg) and chronic weight management (Saxenda, 3.0 mg). The LEADER trial demonstrated a significant reduction in major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.8–1.5%, weight loss (4–8% body weight at 3.0 mg dose), cardiovascular event reduction (leader: 13% rrr for mace). 10 sources indexed (2017–2025), with 5 interaction records on file.
Core mechanism
A GLP-1 analogue with 97% homology to native human GLP-1, modified with a fatty acid side chain enabling albumin binding and extending the half-life to ~13 hours. Activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety through central appetite regulation.
Inject subcutaneously in abdomen, thigh, or upper arm at any time of day, with or without food. Consistent timing recommended.
Both liraglutide and berberine lower blood glucose. Both also slow GI motility, compounding GI side effects (nausea, vomiting, diarrhea). Significant hypoglycemia risk when combined.
Recommendation: Monitor glucose closely. GI side effects may be additive. Start berberine at low dose if combining.
Liraglutide is a daily GLP-1 receptor agonist used for type 2 diabetes and weight management. Chromium improves insulin sensitivity. On liraglutide alone, hypoglycemia is uncommon, but additive glucose-lowering can become clinically meaningful when chromium is layered on top of a regimen that also includes insulin or a sulfonylurea.
Recommendation: If liraglutide is your only diabetes medication, chromium can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether those agents need to be reduced first.
Alpha-lipoic acid improves insulin sensitivity and liraglutide augments glucose-dependent insulin release. On liraglutide alone the hypoglycemia risk is low, but additive effects can matter when ALA is added on top of insulin or a sulfonylurea. ALA has also rarely triggered insulin autoimmune syndrome with severe spontaneous hypoglycemia.
Recommendation: If liraglutide is your only diabetes medication, ALA can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent needs a dose reduction first.
Liraglutide commonly causes nausea, especially during dose titration. Ginger reduces nausea in pregnancy, postoperative, and chemotherapy-induced nausea meta-analyses and is one of the best-tolerated antinausea options. Combined with liraglutide, ginger can reduce GLP-1 nausea without affecting glycemic or weight efficacy.
Recommendation: If liraglutide nausea is a problem, ginger 1-2 g/day (capsules or tea) is a reasonable adjunct. Take it with meals. If you are also on warfarin or another anticoagulant, discuss with your prescriber first.
Psyllium husk reduces postprandial glucose and HbA1c in type 2 diabetes by slowing carbohydrate absorption. Liraglutide also slows gastric emptying and lowers postprandial glucose. Combined, the two reduce postprandial spikes without driving hypoglycemia. Additive GI slowing can intensify bloating, constipation, or early satiety. Liraglutide is injected subcutaneously so psyllium's drug-binding effect does not apply to the medication itself.
Recommendation: Psyllium (5-10 g/day, split with meals) is a reasonable adjunct on liraglutide. Drink plenty of water and increase the dose gradually to limit bloating. Separate psyllium from any oral medications by at least 2-4 hours to preserve their absorption.
Numbered references. Citations throughout the page link here.
Patel JP, Hardaswani D, Patel J et al.. Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. Cureus. 2025
Karimi MA, Gholami Chahkand MS, Dadkhah PA et al.. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Frontiers in pharmacology. 2025
Teng Y, Fan X, Yu R et al.. Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis. BMC endocrine disorders. 2024
Xie Z, Yang S, Deng W et al.. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical epidemiology. 2022
Quarenghi M, Capelli S, Galligani G et al.. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of clinical medicine. 2025
Liraglutide 3.0mg daily plus lifestyle therapy resulted in significantly greater BMI reduction (-5.01%) compared to placebo (+0.44%) in adolescents aged 12-17 with obesity over 56 weeks
Liraglutide significantly reduced the risk of nephropathy events (new-onset macroalbuminuria, doubling of serum creatinine, renal replacement therapy, or renal death) by 22% in the LEADER trial
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack